PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2019-10-11

Date Title Company
11-Oct-2019 Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day Kodiak Sciences Inc.
11-Oct-2019 Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration Allergan plc
11-Oct-2019 Agrivida Announces Interim CEO Agrivida Inc.
11-Oct-2019 Specialdocs Welcomes Two Key Members to Expanding Executive Team Specialdocs Consultants
11-Oct-2019 Focus day announced for SMi’s 11th annual RNA Therapeutics conference 2020 SMI
11-Oct-2019 Clinical Professionals CEO invited to write in the Parliamentary Review Clinical Professionals
11-Oct-2019 IME Medical Electrospinning Appoints Three Seasoned Medtech and Biopharmeutical Industry Experts to its Board of Directors B3C newswire
11-Oct-2019 Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301 Kodiak Sciences Inc.
11-Oct-2019 Informa Pharma Intelligence Launches New Product Citeline Engage Informa Pharma Intelligence
11-Oct-2019 Ascent Health Hires Senior Ex-Flipkart Executive as VP - Engineering Purple Quarter
11-Oct-2019 AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress AbbVie
11-Oct-2019 UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases UCB
11-Oct-2019 Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis Novartis
11-Oct-2019 Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S. Kangpu Biopharmaceuticals